Matthias Wirth (PhD) is a molecular oncology researcher and junior group leader at the University Medical Center Göttingen with a focus on therapy resistance, immune modulation, and translational cancer research. After completing a PhD on transcriptional vulnerabilities in tumor cells, he held postdoctoral positions in Düsseldorf and Berlin (Charité), where he investigated MYC biology, synthetic lethality, and immune escape mechanisms. A central interest of his research is the interplay between oncogenic transcription factors like MYC and post-translational modifiers such as SUMOylation. He contributed to studies demonstrating that SUMO-mediated repression of antigen presentation plays a role in immune escape in cancer, and that pharmacological SUMO inhibition can help restore immune recognition. His translational approach integrates functional genomics, CRISPR screening, and multi-omics technologies with patient-derived organoid models and immune co-cultures. In collaboration with medicinal chemists, he is also developing small-molecule inhibitors targeting key regulatory nodes within these pathways. Dr. Wirth combines mechanistic insight with a focus on therapeutic application, aiming to translate molecular discoveries into cancer treatments.